GLI1 and neoplasm: In contrast to the cell culture studies, treatment with single agent BKM120, a pan-PI3K antagonist, or arsenic trioxide [215], as a GLI antagonist, did not inhibit LSCC tumor growth or GLI1 expression in vivo, whereas combination treatment demonstrated tumor regression and inhibition of GLI1 expression [196].